Effects of interleukin-6 treatment on neurovascular function, nerve perfusion and vascular endothelium in diabetic rats

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 689-699

  Cotter, M A ^a   Gibson, T M ^a   Nangle, M R ^a   Cameron, N E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Diabetes; EDHF; Interleukin 6; neuropathy; Nitric oxide; Vascular endothelium

Indexed keywords

ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HYDROGEN; INTERLEUKIN 6; NITRIC OXIDE; STREPTOZOCIN;

ALLODYNIA; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; CONTROLLED STUDY; HYDROGEN CLEARANCE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MECHANICAL STRESS; MICROELECTRODE; NERVE PERFUSION; NERVE STIMULATION; NONHUMAN; POLAROGRAPHY; POST HOC ANALYSIS; RENAL ARTERY; SAPHENOUS NERVE; SENSORIMOTOR FUNCTION; SENSORY NERVE CONDUCTION; SPINAL GANGLION; STOMACH FUNDUS; STREPTOZOCIN DIABETES; TEMPERATURE STRESS; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 77958090014     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01221.x     Document Type: Article

References (54)

1. Cameron NE, Eaton SEM, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-1988.
2. Vinik A, Pittenger G, Stansbury K, Park TS, Erbas T, Skeen M. Neurotrophic factors. In: Gries FA, Cameron NE, Low PA, Ziegler D eds. Textbook of Diabetic Neuropathy. Stuttgart, Germany: Thieme, 2003; 129-143.
3. Gadient RA, Otten UH. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997; 52: 379-390.
4. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Ann Rev Immunol 1997; 15: 797-819.
5. Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res 2003; 4: 303-312.
6. Ikeda K, Iwasaki Y, Shiojima T, Kinoshita M. Neuroprotective effect of various cytokines on developing spinal motoneurons following axotomy. J Neurol Sci 1996; 135: 109-113.
7. Matsuda S, Wen TC, Morita F etal. Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils. Neurosci Lett 1996; 204: 109-112.
8. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 1994; 153: 3811-3821.
9. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol 2005; 288: H1016-H1021.
10. Minghini A, Britt LD, Hill MA. Interleukin-1 and interleukin-6 mediated skeletal muscle arteriolar vasodilation: in vitro versus in vivo studies. Shock 1998; 9: 210-215.
11. Zhong J, Dietzel ID, Wahle P, Kopf M, Heumann R. Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. J Neurosci 1999; 19: 4305-4313.
12. Hirota H, Kiyama H, Kishimoto T, Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 1996; 183: 2627-2634.
13. Andriambeloson E, Baillet C, Vitte P-A, Garotta G, Dreano M, Callizot N. Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology 2006; 26: 32-42.
14. Cameron NE, Cotter MA. The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. Exp Neurol 2007; 207: 23-29.
15. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2353-2362.
16. Gibson TM, Cotter MA, Cameron NE. Effects of (-lipoic acid on impaired gastric fundus innervation in diabetic rats. Free Radic Biol Med 2003; 35: 160-168.
17. Kihara M, Low PA. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 1995; 132: 180-185.
18. Maxfield EK, Cameron NE, Cotter MA. Effect of diabetes on reactivity of sciatic vasa nervorum in rats. J Diabet Complications 1997; 11: 47-55.
19. Coppey LJ, Gellett JS, Yorek MA. Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: effects of diabetes in type 1 and type 2 diabetic models. Endothelium 2003; 10: 89-94.
20. Randall LO, Sellito JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111: 409-419.
21. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32: 77-88.
22. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Meth 1994; 53: 55-63.
23. Cameron NE, Cotter MA, Hohman TC. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia 1996; 39: 172-182.
24. Nangle MR, Gibson TM, Cotter MA, Cameron NE. Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats. Planta Med 2006; 72: 494-500.
25. + release in isolated rat renal arteries. Br J Pharmacol 2001; 132: 1558-1564.
26. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int Rev Neurobiol 1989; 31: 355-438.
27. 2 clearance curves used to measure blood flow in rat sciatic nerve. J Physiol 1989; 414: 35-54.
28. Cameron NE, Cotter MA, Harrison J. The effects of diabetes on motor nerve conduction velocity in different branches of the rat sciatic nerve. Exp Neurol 1986; 92: 757-761.
29. Cameron NE, Mathias CJ. Structure and function of the nervous system. In: Gries FA, Cameron NE, Low PA, Ziegler D eds. Textbook of Diabetic Neuropathy. Stuttgart, Germany: Thieme, 2003; 40-63.
30. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against diabetic sensory neuropathy. Brain Res 1994; 634: 7-12.
31. Lee JH, McCarty RC. Glycemic control of pain threshold in diabetic and control rats. Physiol Behav 1990; 47: 225-230.
32. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C β-isoform inhibitor, LY333531, on neural and vascular function in streptozotocin-diabetic rats. Clin Sci 2002; 103: 311-321.
33. Cameron NE, Jack AM, Cotter MA. Effect of α-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001; 31: 125-135.
34. Flatters SJ, Fox AJ, Dickenson AH. Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res 2003; 984: 54-62.
35. Khan GM, Chen SR, Pan HL. Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience 2002; 114: 291-299.
36. Jarvis MF, Wessale JL, Zhu CZ et al. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol 2000; 388: 29-35.
37. Cameron NE, Tuck Z, McCabe L, Cotter MA. Effects of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion and function in experimental diabetes. Diabetologia 2001; 44: 1161-1169.
38. Oka T, Oka K, Hosoi M, Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res 1995; 692: 123-128.
39. Choi HS, Ju JS, Lee HJ, Kim BC, Park JS, Ahn DK. Effects of intracisternal injection of interleukin-6 on nociceptive jaw opening reflex and orofacial formalin test in freely moving rats. Brain Res Bull 2003; 59: 365-370.
40. Bianchi M, Maggi R, Pimpinelli F et al. Presence of a reduced opioid response in interleukin-6 knock out mice. Eur J Neurosci 1999; 11: 1501-1507.
41. Xu XJ, Hao JX, Andell-Jonsson S, Poli V, Bartfai T, Wiesenfeld-Hallin Z. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine 1997; 9: 1028-1033.
42. Sagara M, Satoh J, Wada R et al. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996; 39: 263-269.
43. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
44. Streit WJ, Semple rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol 1998; 152: 74-87.
45. Shuto T, Horie H, Hikawa N et al. IL-6 up-regulates CNTF mRNA and enhances neurite regeneration. Neuroreport 2001; 12: 1081-1085.
46. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006; 26: 562-570.
47. Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol 2007; 292: H1728-1736.
48. Burnard RC, Price SA, McElhaney M, Barker D, Tomlinson DR. Expression of axotomy-inducible and apoptosis-related genes in sensory nerves of rats with experimental diabetes. Mol Brain Res 2004; 132: 235-240.
49. Dixon A, Wells CC, Singh S, Babayan R, Maric C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol 2007; 27: 120-128.
50. Ugochukwu NH, Figgers CL. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpha, and activates IL-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats. J Nutritional Biochem 2007; 18: 120-126.
51. Thier M, Marz P, Otten U, Weis J, Rose-John S. Interleukin-6(IL-6)andits soluble receptor support survival of sensory neurons. J Neurosci Res 1999; 55: 411-422.
52. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetologica 1999; 36: 67-72.
53. Kimura K, Tsuda K, Moriwaki C et al. Leukemia inhibitory factor relaxes arteries through endothelium-dependent mechanism. Biochem Biophys Res Comm 2002; 294: 359-362.
54. Bauersachs J, Popp R, Hecker M, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996; 94: 3341-3347.